Abstract The endothelins and their G protein-coupled receptors A and B have been implicated in numerous diseases and have recently emerged as pivotal players in a variety of malignancies. Tumors overexpress the endothelin 1 (ET-1) ligand and the endothelin-A-receptor (ET A R). Their interaction induces tumor growth and metastasis by promoting tumor cell survival and proliferation, angiogenesis, and tissue remodeling. On the basis of results from xenograft models, drug development efforts have focused on antagonizing the autocrine-paracrine effects mediated by ET-1/ET A R. In this review, we discuss a novel role of the endothelin-B-receptor (ET B R) in tumorigenesis and the effect of its blockade during cancer immune therapy.We highlight key characteristics of the B receptor such as its specific overexpression in the tumor compartment; and specifically, in the tumor endothelium, where its activation by ET-1suppressesT-cell adhesion and homing to tumors. We also review our recent findings on the effects of ET B R-specific blockade in increasing T-cell homing to tumors and enhancing the efficacy of otherwise ineffective immunotherapy.
Background
The endothelin system
The endothelin system comprises four endothelin (ET) peptide ligands, ET-1, 2, 3 (1) , and the more recently discovered ET-4 (2); their two G protein-coupled receptors (GPCR), ET A R (3) and ET B R (4); and the endothelin-converting enzymes (ECEs), which catalyze the generation of the biologically active ETs. ETs derive from precursor proteins after cleavage by membranebound metalloproteinase ECEs (5) and are well known for their overall vasoconstricting activity. Among them, ET-1 is the most potent ligand and the most widely expressed in endothelial cells (6) . The endothelin peptides exert their function through binding to their cognate receptors A and B, whereby they trigger divergent intracellular effects by activating numerous downstream signaling pathways. Members of the endothelin system have been identified in neuronal, renal, and vascular tissues, and their involvement has been well documented in an array of physiological processes such as embryonic development, reproduction, angiogenesis, and cardiovascular homeostasis (4, 7 -9) .
Role of the endothelin system in disease
The role of the endothelin system has been well characterized in cardiovascular and renal disorders (10 -13) . ET-1 is produced by endothelial cells and exerts autocrine-paracrine functions by binding to ET A R and ET B R on vascular endothelial cells and pericytes. Balanced activation of the two receptors maintains vascular tone and regulates endothelial cell proliferation (14, 15) , whereas imbalance in this system contributes to the onset of hemodynamic disorders. The same applies to the renal vasculature, in which endothelins play a major role in maintaining normal vascular tone through both the A (13, 16) and B receptor (17) . Endothelins and their receptors have also been implicated in pulmonary hypertension (18) , asthma (19) , and pulmonary fibrosis. ET-1 immunostaining was detected in normal lung epithelium and vasculature (20) . ET A R is found on vascular and airway smooth muscle, whereas ET B R is mostly often found on the endothelium and smooth muscle cells. Activation of both A and B receptors on lung smooth muscle cells results in vasoconstriction, whereas ET B R activation alone leads to bronchoconstriction (21) .
ET A R and ET B R are also involved in inflammatory processes. Both ET A R and ET B R expression in bronchial smooth muscle cells is increased upon experimentally induced airway inflammation (22) . ET A R activation is also required for endotoxininduced inflammation (23) or T-cell homing to the lungs after allergenic or inflammatory stimuli, whereas experimental airway inflammation is abrogated by ET A R inhibition (24, 25) . The role of the endothelin axis in inflammation extends beyond the respiratory tract. ET A R activation mediates renal inflammation and transforming growth factor-h (TGF-h) production in diabetes (26) . Owing to its proinflammatory properties (27, 28) , ET-1 contributes to the progression of various diseases like glomerulosclerosis and atherosclerosis and the pathogenesis of autoimmune diseases such as scleroderma and lupus erythematosus (29, 30) . Importantly, ET-1 is synthesized by lymphocytes and other leukocytes, and has been shown to activate the proinflammatory transcriptional factor nuclear factor-nB (NF-nB) in human monocytes via ET B R and to stimulate the production of inflammatory interleukins and tumor necrosis factor-a (TNF-h) (ref. 31) . ET-1 is also a chemoattractant for monocytes in vitro, via stimulation of IL-8/CXCL8 and monocyte chemoattractant protein-1 (MCP-1)/CCL2 (32, 33) .
Role of the endothelin system in cancer Endothelin 1. The role of the endothelin system in cancer has been reviewed extensively by Bagnato and colleagues (34) and others in the field. Kusuhara and colleagues were among the first to report ET-1 overexpression by breast, colon, stomach, prostate, and glioblastoma cell lines (35, 36) . Ovarian, neuroblastoma, and human papilloma virus (HPV)-positive human cervical carcinoma cell lines also overexpress ET-1 (37, 38) , whereas increased immunopositivity for ET-1 was detected in vivo in human colorectal cancer (39) . Compiling clinical evidence shows elevated plasma ET-1 levels in patients diagnosed with various solid tumors, including hepatocellular, gastric, and prostate cancer (40 -42) . Interestingly, condensed breath of patients with non small cell lung carcinoma (NSCLC) showed increased ET-1 levels (43), proposing ET-1 as an early detection marker (44) . Finally, in ovarian carcinoma, high ET-1 levels were detected in ascites (45) . In summary, the endothelin 1 ligand is overexpressed by many tumors.
Strong evidence suggests a role for members of the endothelin system in the growth and progression of multiple tumors. Exogenous addition of ET-1 to a range of cell lines promotes various aspects of tumorigenesis. In prostate cancer cell lines, ET-1 increased survival and proliferation (42, 46) . Exposure of breast cancer cells to ET-1 led to invasive phenotype, which involved matrix metalloproteinase (MMP) activity (47) . The same mechanism occurred in osteosarcoma, in which ET-1 was shown to promote MMP-2 and MMP-9 induction (48). Lastly, in colon cancer ET-1 overexpression was shown to rescue cancer cells from apoptosis and growth arrest by promoting the oncogene h-catenin (49) .
ET A R. The effects of ET-1 on cancer cells are mostly mediated by ET A R. Importantly, ET A R was shown to be overexpressed in renal and cervical cancer cell lines (50, 51) as well as several cancer types in vivo including colorectal, bladder, prostate, and nasopharyngeal carcinomas (46, 52 -55) . ET A R is also overexpressed in approximately 85% of primary and metastatic ovarian carcinomas. In this study, all ovarian carcinomaderived cell lines were positive for both ET-1 and ET A R mRNA (56) . Concomitant up-regulation of ET-1 and ET A R on tumor cells contributes to cell autonomy and malignant progression and triggers complex pathways driving tumorigenesis, including cell proliferation, inhibition of apoptosis, matrix remodeling, invasion, and metastatic dissemination (57) . ET-1/ ET A R also increases invasion and migration of tumor cells through downstream effects on MMPs, cadherins, connexins, and integrins. Increased cell proliferation is mediated by increased Ca 2+ uptake and activation of the PKC, PLC, MAPK, and AKT pathways. ET-1/ET A R interaction can also activate the AKT and the NF-?B pathways to promote tumor cell survival (34) .
The mitogenic activity of ET-1 can also be augmented by growth factors (57) . One example is the cross-signaling between ET A R and the epidermal growth factor receptor (EGFR) (ref. 34) . EGFR has been identified as a downstream mediator of ET Areceptor activation by ET-1 in ovarian cancer (58) . The mechanism is triggered by ET-1, which causes EGFR transactivation. This event leads to activation of the RAS/MAPK pathway and AKT activation through the formation of Shc/Grb-2 complexes (45, 58) , subsequently contributing to the mitogenic signaling induced by ET-1. This cross-signaling between the EGFR and ET A R pathways provides the rationale for combining EGFR inhibitors with ET A R antagonists to treat ovarian carcinoma. It has been shown that ZD4054, a specific ET A R antagonist, reduces ET-1-induced EGFR transactivation, whereas the EGFR inhibitor gefitinib significantly inhibited EGF and ET-1 induced EGFR phosphorylation (59) . This drug combination simultaneously disables multiple signaling pathways, offering improvements in ovarian carcinoma treatment (59) .
ET-1 increases the expression of cyclooxygenase (COX)-1 and COX-2, prostaglandin (PG)E 2 , and VEGF production by ovarian cancer cells via ET A R activation (60) . The effect of ET-1 on VEGF expression is mediated through HIF-1a (61) . Elevated expression of ET-1 has been associated with increased VEGF expression, lymphatic vessel invasion, and unfavorable outcome in invasive ductal breast carcinoma (62) . A correlation between ET-1 expression and VEGF expression has also been shown in lung cancer (63) . Additionally, inhibition of human ovarian tumor growth in nude mice after treatment with the potent ET A R-selective antagonist ABT-627 was associated with reduced COX-2 and VEGF expression by the tumor (60). Thus, overexpression of the ligand ET-1 and its receptor, ET A R, account for autocrine-paracrine activation of the endothelin axis in many solid tumors, which plays important and multifaceted roles in tumor cell progression. The ET A R is therefore a very attractive target for cancer therapy.
ET B R. Investigation of the role of ET-1/ET B R in tumor cell biology has been more limited. In normal cells, ET B R counterregulates ET-1/ET A R activity through multiple mechanisms including increasing production of nitric oxide, promoting ET-1 clearance, triggering apoptotic pathways, and blocking cell growth; but it is unclear whether such antagonism also operates in tumor cells (64) . Interestingly, ET B R is overexpressed and correlates with melanoma development and progression. Expression profiling of human melanoma biopsies indicated ET B R overexpression to be associated with aggressive tumor phenotype (65) , and ET B R was proposed as tumor progression marker (66) . Underscoring the role of ET B R in melanoma growth, the specific antagonist BQ-788 was found to inhibit the growth of human melanoma cell lines and to reduce human melanoma tumor growth in a nude mouse model (67, 68) . The B receptor is also expressed in Kaposi's sarcoma and glioblastoma (69 -71) .
The role of ET B R in cancer angiogenesis has been thoroughly investigated and reviewed by Bagnato and colleagues (34) . ET-1 has been shown to directly promote tumor angiogenesis by inducing endothelial cell survival, proliferation, and invasion through ET B R (61). ET-1 promotes angiogenesis also indirectly, by upregulating VEGF production in the vasculature, also through ET B R activation (72) , and increases vascular permeability through VEGF in response to tissue hypoxia (73) . Furthermore, ET-1 upregulates expression of the extra domain-B containing fibronectin (EDB + FN) in human vascular endothelial cells (74, 75) . EDB + FN is a recently proposed marker of angiogenesis expressed in human cancers and in ocular neovascularization in patients with proliferative diabetic retinopathy. There is a strong correlation between ET B R and VEGF expression in a number of different tumor specimens (76) .
and undergone preclinical and clinical testing. Some compounds have preferential A or B receptor inhibitory activity, whereas others exhibit mixed A and B antagonism. Given the prominent role of ET A R in tumor cell biology, ET A R-selective antagonists have been developed more extensively than ET B R antagonists to treat malignancy (see Table 1 ). The first ET A Rselective peptide antagonist, BQ-123 (77), was shown to inhibit cervical cancer growth in preclinical models (78) . Furthermore, nonpeptide ET A R antagonists such as Atrasentan, ZD4054, and YM598 have been shown to have a static effect on ovarian tumor growth in xenograft models (79) ; to delay progression of prostate cancer (80, 81) ; and to attenuate growth and metastasis of human gastric carcinoma (82) Table 1 . Notably, phase II results with Atrasentan in hormone refractory prostate cancer (HRPC) were encouraging (83) . However, subsequent phase III trials in metastatic and nonmetastatic HRPC showed no significant therapeutic effects despite evidence of biologic effects on serum markers of disease burden (84, 85) . Large geographic differences in the median time to progression were also noted; U.S. patients showed less gain in time to progression relative to non-U.S. patients (85) . Given the role of ET B R in melanoma cells, ET B R antagonists have been tested in (67, 68) . Interestingly, IRL1620, an ET B R agonist, was shown to improve both delivery and therapeutic efficacy of paclitaxel in breast tumor-bearing mice (86) .
ET B R and the tumor endothelial barrier to T-cell homing. The focus of cancer therapy targeting ET-1 to date has been to antagonize the autocrine-paracrine effects of ET-1 on tumor cells, mediated mainly by ET A R. Our laboratory recently showed a novel application of ET B R blockade in tumor therapy. Specifically, ET B R blockade at the tumor endothelium proved to be therapeutically efficient for tumor immune therapy ( Fig. 1)  (ref. 87) . The success of immune therapy depends on the ability of effector T cells to infiltrate tumors. Although current tumor vaccines have proven effective in producing an antitumor immune response as measured by blood assays, they have fallen short of clinical expectations. Endothelium is a crucial controller of T-cell trafficking in homeostasis, autoimmunity, and transplantation in humans. We showed that the endothelial barrier also exists in tumors and is partly mediated by ET B R.
This mechanism was uncovered in human ovarian cancer, in which endothelial cells were microdissected from tumors with brisk tumor-infiltrating lymphocytes (TILs) and tumors lacking TILs, to examine differences in their molecular profile. ET B R emerged as one of the few genes overexpressed in tumor endothelial cells from tumors lacking TILs by Affymetrix array analysis (87) . ET B R was mostly localized to the endothelium and some stroma cells by immunostaining in human ovarian cancers. ET B R mRNA or protein overexpression was associated with absence or paucity of TILs, especially of intraepithelial (also called intratumoral) T cells (87) . These are T cells infiltrating the epithelial component of the tumor (tumor islets), which predict longer survival in ovarian cancer (88) . ET-1 is (34) , and it was found that ET-1 mRNA was significantly higher in microdissected (cytokeratin-positive) tumor cells from tumors lacking TILs relative to tumors with brisk TILs. Thus, the entire ET-1/ET B R (tumor-endothelial) paracrine axis seems upregulated in ovarian cancers lacking TILs. Importantly, we showed that recombinant human ET-1 blocks adhesion of activated T cells to human umbilical vein endothelial cells in vitro. These results establish a vascular mechanism of tumor immune evasion mediated by the endothelin system (87) .
TNF-a is a major inflammatory cytokine implicated in carcinogenesis, tumor angiogenesis, and progression, and it is upregulated in ovarian cancer (89) . It has been previously reported that the overall TNF-a mRNA levels are similar in ovarian tumors with or without intraepithelial T cells (88) . This was counterintuitive, as TNF-a is a major factor activating endothelium and promoting adhesion of T cells. It has been now found that ET-1 efficiently blocks adhesion of T cells to endothelial cells even when endothelial cells are activated with TNF-a (87). This observation explains the paradox of how tumors may exhibit inflammation yet be prohibitive to T-cell infiltration, thus establishing immune privilege even in the face of inflammation.
ET-1 was found to abrogate T-cell adhesion to endothelium via ET B R and through suppression of endothelial intercellular adhesion molecule-1 (ICAM-1) expression at base line as well as following endothelial activation with TNF-a. Furthermore, it was found that ET B R-induced suppression of ICAM-1 expression and surface clustering was mediated by nitric oxide (NO). ET B R blockade with the selective antagonist BQ-788 upregulated endothelial ICAM-1 expression, promoted ICAM-1 clustering at the cell surface, and restored adhesion of T cells to ET-1-treated endothelial cells. ICAM-1 neutralizing antibody abrogated the effect of ET B R blockade to promote T-cell adhesion to endothelium in vitro (87). These observations indicate that the endothelin system is crucial for controlling lymphocyte homing in tumors and that endothelial ET B R overexpression, which can sway the vascular ET A R/ET B R balance toward ET B R hyperactivity, results in suppression of T-cell homing. This evidence is substantiated by complementary data in lung inflammation; ET A R activation is required for endotoxin-induced inflammation (23) , whereas T-cell homing to lungs in response to an inflammatory stimulus is abrogated by ET A R blockade (24, 25) . Thus, vascular ET A R activation results in increased T-cell homing, whereas increased ET B R signaling facilitates immune privileged status.
ET B R blockade in cancer immune therapy. To test the activity of ET B R in controlling T-cell homing to tumors and the effects of its blockade in vivo in the context of immunotherapy, vaccine approaches that have no efficacy in delaying tumor growth were used. It was found that vaccine failure was associated with poor accumulation of T cells at the tumor site, in spite of detectable systemic antitumor immune response. ET B R blockade with specific antagonist BQ-788 greatly enhanced the efficacy of prevention and therapeutic vaccines. BQ-788 did not increase systemic immune response to the vaccine in vivo, but rather greatly enhanced T-cell infiltration in tumors following vaccine (87) . This was attenuated by ICAM-1 neutralizing antibody, confirming the requirement for adhesive interactions mediated by ICAM-1 following ET B R blockade in vivo. Furthermore, BQ-788 markedly increased homing of T-cells to tumors after adoptive transfer in mice. Thus, in many tumors there is hyperactivation of a paracrine ET-1/ET B R axis established between tumor cells and endothelium, whereby tumor cells overexpress and release ET-1 whereas the tumor endothelium overexpresses ET B R. This axis tonically suppresses T-cell homing (even in the presence of tumor inflammation), and can be disrupted by ET B R blockade, which in vivo markedly enhances tumor immune therapy (87) . This mechanism may not be unique to ovarian cancer. For example, ET B R is also overexpressed in breast cancer vasculature (86) . Interestingly, ET B R upregulation predicts poor outcome both in breast and ovarian cancer (47, 90) . The mechanisms underlying ET B R overexpression in tumor endothelium are not fully understood, but VEGF may be implicated (91, 92) .
Our results argue that ET B R antagonists warrant testing in combination with passive or adoptive immunotherapy. There are unique features that render ET B R blockade an attractive strategy in cancer immunotherapy. First, as outlined above, the axis ET-1/ ET B R seems to be selectively upregulated in the tumor compartment but not in normal tissues. Indeed, in mouse experiments, ET B R blockade by BQ-788 did not result in systemic inflammation or illness, and frequency of CD45 + lymphocytes or CD3 + T cells in liver, spleen, lungs, or kidneys after vaccine or adoptive T-cell transfer was not affected by . This is in contrast to current immunomodulatory approaches, which achieve systemic activation of effector cells by attenuating peripheral tolerance or other homeostatic checkpoint mechanisms and can result in significant autoimmune toxicity (93) . Second, ET B Rselective antagonists, including BQ-788, have been tested in humans and are well tolerated even in patients with cardiovascular disease (94 -96) . Thus, ET B R can be pharmacologically perturbed with existing drugs to enhance the efficacy of immune therapy. Third, ET B R blockade is likely to have also direct antiangiogenic effects through suppression of endothelial nitric oxide. Unlike in patients with sepsis (97) , NO inhibition is safe and has been well tolerated in cancer patients (98) . Although the anticancer effect of ET B R (or NO) blockade as monotherapy may be modest, the concomitant administration of immunotherapy may act synergistically against angiogenesis (86, 99) .
Implications for pure ET A R antagonists. Currently, on the basis of results obtained mostly with xenograft tumor models in immunodeficient mice, cancer therapy targeting ET is focused on ET A R blockade. However, previous evidence shows that ET A R signaling is required for T-cell homing (24, 25) , whereas our work indicates that increased ET B R activity in tumor endothelium results in reduced T-cell homing and ET B R blockade is required to improve T-cell homing to tumors. Because of the tonic antagonism between ET A R and ET B R signaling in the vasculature, pharmacologic ET A R blockade could tilt the balance toward increased ET B R signaling in the tumor vasculature. This could possibly result in increased angiogenesis and, on the basis of our work, could suppress T-cell homing to tumors. It has been previously shown that patients with ovarian cancer whose tumors are infiltrated by intraepithelial T cells survive longer (88), a concept validated by several groups (100 -103). Similar observations were made in other solid tumors. In colon cancer, tumor-infiltrating T cells predict survival better than conventional anatomical staging (104) , whereas in prostate cancer TIL represent a strong independent prognosticator of longer survival (105) . Although the function of tumor-infiltrating T cells is not fully understood, it is possible that they contribute to controlling tumor growth during or after conventional cancer therapy. For example, the long-term therapeutic effects of VEGF receptor 2 blockade, a major antiangiogenic pharmacologic intervention, were fully depended on CD8 + T cell infiltration in tumors (106) . Furthermore, conventional chemotherapy agents have immunomodulatory effects and their long term efficacy may depend in part on immune effector mechanisms (107) . If this were the case, ET A R blockade alone might increase ET B R signaling and reduce T-cell infiltration in tumors. This could negate some of the potential efficacy of cancer therapies and explain in part the failure of pure ET A R antagonists to produce significant clinical results in tumors in which TIL may affect survival. Our results argue that ET A R/ET B R mixed antagonists might offer the advantage of simultaneously targeting the tumor cell (through ET A R) and enhancing antitumor immune mechanisms (through vascular ET B R) and should be the focus of future therapy.
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